Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.
Alnylam Pharmaceuticals, Inc. (ALNY) has a market cap of $45.29B with year-over-year revenue growth of +65.2%. Net margin stands at 8.4%. The stock trades at a P/E ratio of 144.3.
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, ALNY posted revenue growth of +65.2% and trades at a P/E of 144.3.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.